Browse > Article
http://dx.doi.org/10.1016/j.jgr.2014.07.002

Effect of Korean Red Ginseng supplementation on dry eye syndrome in glaucoma patients - A randomized, double-blind, placebo-controlled study  

Bae, Hyoung Won (Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine)
Kim, Ji Hyun (Siloam Eye Hospital)
Kim, Sangah (Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine)
Kim, Minkyo (Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine)
Lee, Naeun (Department of Ophthalmology, Hallym Hospital)
Hong, Samin (Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine)
Seong, Gong Je (Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine)
Kim, Chan Yun (Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine)
Publication Information
Journal of Ginseng Research / v.39, no.1, 2015 , pp. 7-13 More about this Journal
Abstract
Background: Many patients with glaucoma have difficulty using antiglaucoma eye drops because of dry eye symptom. In this prospective, randomized, double-blind, placebo-controlled study, we evaluated the effect of Korean Red Ginseng on dry eye syndrome in patients with glaucoma treated with antiglaucoma eye drops. Methods: Forty-nine participants were allocated to the Korean Red Ginseng (3 g/day; n = 24) or placebo (n = 25) groups for 8 weeks. Tear film stability, fluorescein corneal staining, conjunctival hyperemia, tear production, grade of meibomian gland dysfunction, and dry eye questionnaire (Ocular Surface Disease Index) were evaluated at baseline and on completion of the treatment. Results: Almost all patients displayed dry eye symptoms and signs at baseline. After the 8-week intervention, Korean Red Ginseng supplementation significantly improved the tear film stability and total Ocular Surface Disease Index score, as compared to placebo (p < 0.01). Conclusion: Korean Red Ginseng supplementation may provide an additional treatment option for dry eye and patients with glaucoma using antiglaucoma eye drops.
Keywords
dry eye syndrome; glaucoma; Korean Red Ginseng; Panax ginseng;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea 2010;29:618-21.   DOI
2 Oh KJ, Chae MJ, Lee HS, Hong HD, Park K. Effects of Korean red ginseng on sexual arousal in menopausal women: placebo-controlled, double-blind crossover clinical study. J Sex Med 2010;7:1469-77.   DOI
3 Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005;46:2444-50.   DOI
4 Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish 2nd RK, Wilson MR, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary openangle glaucoma. Arch Ophthal 2002;120:714-20.   DOI
5 Hwang SY, Son DJ, Kim IW, Kim DM, Sohn SH, Lee JJ, Kim SK. Korean red ginseng attenuates hypercholesterolemia-enhanced platelet aggregation through suppression of diacylglycerol liberation in high-cholesterol-diet-fed rabbits. Phytother Res 2008;22:778-83.   DOI
6 Baudouin C, Pisella PJ, Fillacier K, Goldschild M, Becquet F, De Saint Jean M, Bechetoille A. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999;106: 556-63.   DOI
7 Abdel-Wahhab MA, Ahmed HH. Protective effects of Korean Panax ginseng against chromium VI toxicity and free radical generation in rat. J Ginseng Res 2004;28:11-7.   DOI
8 Kim WK, Song SY, Oh WK, Kaewsuwan S, Tran TL, Kim WS, Sung JH. Woundhealing effect of ginsenoside Rd from leaves of Panax ginseng via cyclic AMPdependent protein kinase pathway. Eur J Pharmacol 2013;702:285-93.   DOI
9 Lee IA, Hyam SR, Jang SE, Han MJ, Kim DH. Ginsenoside Re ameliorates inflammation by inhibiting the binding of lipopolysaccharide to TLR4 on macrophages. J Agric Food Chem 2012;60:9595-602.   DOI
10 Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999;58:1685-93.   DOI
11 Zang YX, Wang L, Xiao EL, Li SJ, Chen JJ, Gao B, Min GN, Wang ZP, Wu YJ. Ginsenoside-Rd exhibits anti-inflammatory activities through elevation of antioxidant enzyme activities and inhibition of JNK and ERK activation in vivo. Int Immunopharmacol 2013;17:1094-100.   DOI
12 Her Y, Lim JW, Han SH. Dry eye and tear film functions in patients with psoriasis. Jpn J Ophthalmol 2013;57:341-6.   DOI
13 Shimazaki-Den S, Dogru M, Higa K, Shimazaki J. Symptoms, visual function, and mucin expression of eyes with tear film instability. Cornea 2013;32: 1211-8.   DOI
14 Rossi GC, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndromerelated quality of life in glaucoma patients. Eur J Ophthalmol 2009;19:572-9.   DOI
15 Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-51.
16 Pizzarello L, Abiose A, Ffytche T, Duerksen R, Thulasiraj R, Taylor H, Faal H, Rao G, Kocur I, Resnikoff S. VISION 2020: the Right to Sight: a global initiative to eliminate avoidable blindness. Arch Ophthal 2004;122:615-20.   DOI
17 Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, VanDenburgh AM, Chen K, Whitcup SM. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthal 2002;120:1286-93.   DOI
18 Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996;103:138-47.   DOI
19 Garcia-Feijoo J, Sampaolesi JR. A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clin Ophthalmol 2012;6: 441-6.
20 Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res 2011;36:391-8.   DOI
21 Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008;17:350-5.   DOI
22 Narayanan S, Miller WL, McDermott AM. Conjunctival cytokine expression in symptomatic moderate dry eye subjects. Invest Ophthalmol Vis Sci 2006;47: 2445-50.   DOI
23 Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren's syndrome keratoconjunctivitis sicca. Curr Eye Res 1999;19:201-11.   DOI
24 Massingale ML, Li X, Vallabhajosyula M, Chen D, Wei Y, Asbell PA. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea 2009;28: 1023-7.   DOI
25 Yoon KC, Jeong IY, Park YG, Yang SY. Interleukin-6 and tumor necrosis factoralpha levels in tears of patients with dry eye syndrome. Cornea 2007;26:431-7.   DOI
26 Lam H, Bleiden L, de Paiva CS, Farley W, Stern ME, Pflugfelder SC. Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol 2009;147: 198-205.   DOI
27 Sung J, Han KH, Zo JH, Park HJ, Kim CH, Oh BH. Effects of red ginseng upon vascular endothelial function in patients with essential hypertension. Am J Chin Med 2000;28:205-16.   DOI
28 Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004;137:337-42.   DOI
29 Jeon BH, Kim CS, Kim HS, Park JB, Nam KY, Chang SJ. Effect of Korean red ginseng on blood pressure and nitric oxide production. Acta Pharmacol Sin 2000;21:1095-100.
30 Jin YR, Yu JY, Lee JJ, You SH, Chung JH, Noh JY, Im JH, Han XH, Kim TJ, Shin KS, et al. Antithrombotic and antiplatelet activities of Korean red ginseng extract. Basic Clin Pharmacol Toxicol 2007;100:170-5.   DOI
31 Bae EA, Hyun YJ, Choo MK, Oh JK, Ryu JH, Kim DH. Protective effect of fermented red ginseng on a transient focal ischemic rats. Arch Pharm Res 2004;27:1136-40.   DOI
32 Kwak YS, Kyung JS, Kim JS, Cho JY, Rhee MH. Anti-hyperlipidemic effects of red ginseng acidic polysaccharide from Korean red ginseng. Biol Pharm Bull 2010;33:468-72.   DOI
33 Heo JH, Lee ST, Chu K, Oh MJ, Park HJ, Shim JY, Kim M. An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease. Eur J Neurol 2008;15:865-8.   DOI
34 Babayigit A, Olmez D, Karaman O, Bagriyanik HA, Yilmaz O, Kivcak B, Erbil G, Uzuner N. Ginseng ameliorates chronic histopathologic changes in a murine model of asthma. Allergy Asthma Proc 2008;29:493-8.   DOI
35 Baek NI, Kim DS, Lee YH, Park JD, Lee CB, Kim SI. Ginsenoside Rh4, a genuine dammarane glycoside from Korean red ginseng. Planta Med 1996;62:86-7.   DOI
36 Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J 1995;21:221-32.
37 Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthal 2000;118:1489-96.   DOI
38 Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000;107:631-9.   DOI
39 Kim NR, Kim JH, Kim CY. Effect of Korean red ginseng supplementation on ocular blood flow in patients with glaucoma. J Ginseng Res 2010;34:237-45.   DOI
40 Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthal 2000;118:615-21.   DOI
41 Jaenen N, Baudouin C, Pouliquen P, Manni G, Fiqueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Opthalmol 2007;17:341-9.   DOI
42 Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010;29: 312-34.   DOI
43 Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004;23:490-6.   DOI
44 Debbasch C, Brignole F, Pisella PJ, Warnet JM, Rat P, Baudouin C. Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci 2001;42: 642-52.
45 Rivas L, Oroza MA, Perez-Esteban A, Murube-del-Castillo J. Morphological changes in ocular surface in dry eyes and other disorders by impression cytology. Graefes Arch Clin Exp Ophthalmol 1992;230:329-34.   DOI
46 Okada Y. Effects of topical antiglaucoma medications on corneal epithelium as evaluated by gene expression patterns. Cornea 2007;26:S46-54.   DOI
47 Pisella PJ, Debbasch C, Hamard P, Creuzot-Garcher C, Rat P, Brignole F, Baudouin C. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004;45:1360-8.   DOI
48 Xiong C, Chen D, Liu J, Liu B, Li N, Zhou Y, Liang X, Ma P, Ye C, Ge J, et al. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. Invest Ophthalmol Vis Sci 2008;49:1850-6.   DOI
49 Hikichi T, Yoshida A, Tsubota K. Lymphocytic infiltration of the conjunctiva and the salivary gland in Sjogren's syndrome. Arch Ophthal 1993;111:21-2.
50 Stern ME, Gao J, Schwalb TA, Ngo M, Tieu DD, Chan CC, Reis BL, Whitcup SM, Thompson D, Smith JA. Conjunctival T-cell subpopulations in Sjogren's and non-Sjogren's patients with dry eye. Invest Ophthalmol Vis Sci 2002;43: 2609-14.
51 Tsubota K, Fujihara T, Saito K, Takeuchi T. Conjunctival epithelium expression of HLA-DR in dry eye patients. Ophthalmologica 1999;213:16-9.   DOI
52 Grus FH, Dick B, Augustin AJ, Pfeiffer N. Analysis of the antibody repertoire in tears of dry-eye patients. Ophthalmologica 2001;215:430-4.   DOI
53 Rand AL, Asbell PA. Nutritional supplements for dry eye syndrome. Curr Opin Ophthalmol 2011;22:279-82.   DOI
54 Park BG, Jung HJ, Cho YW, Lim HW, Lim CJ. Potentiation of antioxidative and anti-inflammatory properties of cultured wild ginseng root extract through probiotic fermentation. J Pharm Pharmacol 2013;65:457-64.   DOI
55 Barabino S, Rolando M, Camicione P, Ravera G, Zanardi S, Giuffrida S, Calabria G. Systemic linoleic and gamma-linolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea 2003;22:97-101.   DOI
56 Aragona P, Bucolo C, Spinella R, Giuffrida S, Ferreri G. Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjogren's syndrome patients. Invest Ophthalmol Vis Sci 2005;46:4474-9.   DOI
57 Macri A, Giuffrida S, Amico V, Iester M, Traverso CE. Effect of linoleic acid and gamma-linolenic acid on tear production, tear clearance and on the ocular surface after photorefractive keratectomy. Graefes Arch Clin Exp Ophthalmol 2003;241:561-6.   DOI
58 Lee SH, Jung BH, Kim SY, Lee EH, Chung BC. The antistress effect of ginseng total saponin and ginsenoside Rg3 and Rb1 evaluated by brain polyamine level under immobilization stress. Pharmacol Res 2006;54:46-9.   DOI
59 Cho WC, Chung WS, Lee SK, Leung AW, Cheng CH, Yue KK. Ginsenoside Re of Panax ginseng possesses significant antioxidant and antihyperlipidemic efficacies in streptozotocin-induced diabetic rats. Eur J Pharmacol 2006;550: 173-9.   DOI
60 Song SB, Tung NH, Quang TH, Nqan NT, Kim KE, Kim YH. Inhibition of TNFalpha- mediated NF-kappaB Transcriptional Activity in HepG2 Cells by Dammarane- type Saponins from Panax ginseng Leaves. J Ginseng Res 2012;36: 146-52.   DOI
61 Ly S, Yi PF, Shen HQ, Zhang LY, Dong HB, Wu SC, Xia F, Guo X, Wei XB, Fu BD. Ginsenoside Rh2-B1 stimulates cell proliferation and IFN-gamma production by activating the p38 MAPK and ERK-dependent signaling pathways in CTLL-2 cells. Immunopharmacol Immunotoxicol 2014;36:43-51.   DOI